Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
723 F.3d 1363
Fed. Cir.2013Background
- Teva sued Mylan and Sandoz under 35 U.S.C. § 271(e)(2)(A) after ANDA filings challenging Teva’s Copaxone® patents; nine related patents were asserted with common specification.
- Copolymer-1 (active ingredient) is a polypeptide mixture of four amino acids (ala, glu, lys, tyr) in ~6:2:5:1 ratio; molecular-weight properties of polymer samples can be described by averages (Mp, Mn, Mw) or by % of molecules within a defined kDa range.
- The patents’ claims split into two groups: Group I claims specify a molecular weight "about 5–9 kDa" (using average-based language); Group II claims specify a percentage of mole fraction within a kDa range (e.g., >75% between 2–20 kDa).
- District court construed "molecular weight" as Mp, found claims enabled, nonobvious, and that Mylan and Sandoz products infringed; it rejected indefiniteness and prosecution-disclaimer defenses.
- On appeal the Federal Circuit: affirmed infringement and no-invalidity for Group II claims; reversed as to Group I claims for indefiniteness; affirmed district court on enablement and nonobviousness; remanded for further proceedings (and potential injunction modifications).
Issues
| Issue | Teva's Argument | Appellants' Argument | Held |
|---|---|---|---|
| Definiteness of term "molecular weight" (Group I & II) | "Molecular weight" is Mp given specification and prosecution history; Group II uses explicit ranges so are definite | Term ambiguous between Mp, Mn, Mw; prosecution statements inconsistent; skilled artisan cannot ascertain boundaries | Group I claims (average-based "about 5–9 kDa") are indefinite; Group II claims (percent within ranges) are not indefinite |
| Enablement (measuring claimed molecular weight) | Specification plus routine SEC calibration methods (self-standards or universal calibration) enable full scope without undue experimentation | Specification fails to teach which calibration standard; copolymer-1 behavior makes calibration nonroutine; Teva’s post-filing struggles show nonenablement | Affirmed: claims are enabled; district court’s fact findings on routine calibration not clearly erroneous |
| Obviousness of lower-MW copolymer-1 claims | Claimed material differs only slightly from prior art and behaves similarly; prior art and human data show lower MW efficacy | Prior art taught preference for higher MW (taught away); secondary considerations (commercial success, long-felt need, failure of others) support nonobviousness | Affirmed: district court did not err—prior art taught away and secondary considerations support nonobviousness |
| Infringement and scope of "approximately 6:2:5:1" composition | The ratio should be treated as relative proportions; examples limit permissible deviation; accused products fall within acceptable aggregate % deviation | District court appropriately converted ratio to percentages and compared on same scale; accused products differ only ~4–5% aggregate and thus infringe | Affirmed infringement: district court’s conversion to percentages and factual infringement findings not clearly erroneous; no prosecution disclaimer found |
Key Cases Cited
- Biosig Instruments, Inc. v. Nautilus, Inc., 715 F.3d 891 (Fed. Cir. 2013) (definiteness standard: claim indefinite only if not amenable to construction or insolubly ambiguous)
- Wellman, Inc. v. Eastman Chem. Co., 642 F.3d 1355 (Fed. Cir. 2011) (clear-and-convincing proof standard for indefiniteness; de novo review)
- MagSil Corp. v. Hitachi Global Storage Techs., Inc., 687 F.3d 1377 (Fed. Cir. 2012) (enablement requires no undue experimentation across full claim scope)
- Cephalon, Inc. v. Watson Pharm., Inc., 707 F.3d 1330 (Fed. Cir. 2013) (enablement review—legal conclusion with underlying factual findings)
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (claim construction principles and primacy of intrinsic evidence)
- Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448 (Fed. Cir. 1998) (en banc) (de novo review of claim construction)
- Omega Eng’g, Inc. v. Raytek Corp., 334 F.3d 1314 (Fed. Cir. 2003) (prosecution disclaimer requires clear and unmistakable statement)
- Brown & Williamson Tobacco Corp. v. Philip Morris, Inc., 229 F.3d 1120 (Fed. Cir. 2000) (commercial success coextensive with claims creates presumption of nexus)
- Alza Corp. v. Mylan Labs., Inc., 464 F.3d 1286 (Fed. Cir. 2006) (infringement factual findings reviewed for clear error)